{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T21:16:14Z","timestamp":1787174174063,"version":"build-2736575974"},"reference-count":63,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003500","name":"University of Padua","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003500","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007076","name":"Fondazione Italiana per la Ricerca sul Cancro Airc","doi-asserted-by":"publisher","award":["IG 2021"],"award-info":[{"award-number":["IG 2021"]}],"id":[{"id":"10.13039\/501100007076","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.ymthe.2024.07.011","type":"journal-article","created":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T21:07:21Z","timestamp":1721423241000},"page":"3650-3668","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Synergic activity of FGFR2 and MEK inhibitors in the treatment of FGFR2-amplified cancers of unknown primary"],"prefix":"10.1016","volume":"32","author":[{"given":"Andrea","family":"Cavazzoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Salamon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Fumarola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Gallerani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noemi","family":"Laprovitera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Gelsomino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Riefolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Rihawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Porcellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Mazzeschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Naddeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Serravalle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Broseghini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Agostinis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Deas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Roncarati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Durante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Pace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Lauriola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Garajova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George A.","family":"Calin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Bonaf\u00e8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"D\u2019Errico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Giorgio","family":"Petronini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Cairo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Ardizzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Sales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1595-6887","authenticated-orcid":false,"given":"Manuela","family":"Ferracin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2024.07.011_bib1","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1126\/science.1203543","article-title":"A perspective on cancer cell metastasis","volume":"331","author":"Chaffer","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2024.07.011_bib2","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1056\/NEJMra1303917","article-title":"Cancer of unknown primary site","volume":"371","author":"Varadhachary","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.07.011_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13030451","article-title":"Cancer of Unknown Primary: Challenges and Progress in Clinical Management","volume":"13","author":"Laprovitera","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ymthe.2024.07.011_bib4","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1038\/bjc.1998.395","article-title":"A multicentre phase II study of carboplatin and prolonged oral etoposide in the treatment of cancer of unknown primary site (CUPS)","volume":"77","author":"Warner","year":"1998","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ymthe.2024.07.011_bib5","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1080\/02841860701843043","article-title":"Docetaxel and carboplatin combination chemotherapy as outpatient palliative therapy in carcinoma of unknown primary: a multicentre Hellenic Cooperative Oncology Group phase II study","volume":"47","author":"Pentheroudakis","year":"2008","journal-title":"Acta Oncol."},{"key":"10.1016\/j.ymthe.2024.07.011_bib6","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s00280-007-0604-7","article-title":"Multicenter phase-II trial of irinotecan plus oxaliplatin [IROX regimen] in patients with poor-prognosis cancer of unknown primary: a hellenic cooperative oncology group study","volume":"62","author":"Briasoulis","year":"2008","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ymthe.2024.07.011_bib7","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/sj.bjc.6604818","article-title":"Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trial","volume":"100","author":"Huebner","year":"2009","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ymthe.2024.07.011_bib8","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/PPO.0b013e3181c6aa89","article-title":"Paclitaxel\/carboplatin\/etoposide versus gemcitabine\/irinotecan in the first-line treatment of patients with carcinoma of unknown primary site: a randomized, phase III Sarah Cannon Oncology Research Consortium Trial","volume":"16","author":"Hainsworth","year":"2010","journal-title":"Cancer J."},{"key":"10.1016\/j.ymthe.2024.07.011_bib9","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.ejca.2012.01.011","article-title":"Cisplatin alone or combined with gemcitabine in carcinomas of unknown primary: results of the randomised GEFCAPI 02 trial","volume":"48","author":"Gross-Goupil","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ymthe.2024.07.011_bib10","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1002\/1878-0261.13026","article-title":"MicroRNA expression profiling with a droplet digital PCR assay enables molecular diagnosis and prognosis of cancers of unknown primary","volume":"15","author":"Laprovitera","year":"2021","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.ymthe.2024.07.011_bib11","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1001\/jamaoncol.2020.4643","article-title":"Site-Specific and Targeted Therapy Based on Molecular Profiling by Next-Generation Sequencing for Cancer of Unknown Primary Site: A Nonrandomized Phase 2 Clinical Trial","volume":"6","author":"Hayashi","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ymthe.2024.07.011_bib12","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s12967-018-1564-x","article-title":"Genetic characterisation of molecular targets in carcinoma of unknown primary","volume":"16","author":"Clynick","year":"2018","journal-title":"J.\u00a0Transl. Med."},{"key":"10.1016\/j.ymthe.2024.07.011_bib13","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1001\/jamaoncol.2014.216","article-title":"Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies","volume":"1","author":"Ross","year":"2015","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ymthe.2024.07.011_bib14","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1001\/jamaoncol.2015.0939","article-title":"Genomic Profiling of Cancers of Unknown Primary Site: The Next Steps","volume":"1","author":"Varghese","year":"2015","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ymthe.2024.07.011_bib15","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nm.4333","article-title":"Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients","volume":"23","author":"Zehir","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2024.07.011_bib16","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1158\/2159-8290.CD-17-0151","article-title":"AACR Project GENIE: Powering Precision Medicine through an International Consortium","volume":"7","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ymthe.2024.07.011_bib17","doi-asserted-by":"crossref","first-page":"533","DOI":"10.3389\/fonc.2020.00533","article-title":"The Quest for Improving Treatment of Cancer of Unknown Primary (CUP) Through Molecularly-Driven Treatments: A Systematic Review","volume":"10","author":"Lombardo","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ymthe.2024.07.011_bib18","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ejca.2018.02.021","article-title":"Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune checkpoint blockade therapy","volume":"94","author":"Gatalica","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ymthe.2024.07.011_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100407","article-title":"Site-specific therapy in cancers of unknown primary site: a systematic review and meta-analysis","volume":"7","author":"Ding","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.ymthe.2024.07.011_bib20","article-title":"Genetic Characterization of Cancer of Unknown Primary Using Liquid Biopsy Approaches","volume":"9","author":"Laprovitera","year":"2021","journal-title":"Front. Cel Dev. Biol."},{"key":"10.1016\/j.ymthe.2024.07.011_bib21","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1093\/clinchem\/hvad180","article-title":"Frequency and Prognostic Value of Circulating Tumor Cells in Cancer of Unknown Primary","volume":"70","author":"Pouyiourou","year":"2024","journal-title":"Clin. Chem."},{"key":"10.1016\/j.ymthe.2024.07.011_bib22","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20160208","article-title":"Efficient and simple approach to in\u00a0vitro culture of primary epithelial cancer cells","volume":"36","author":"Janik","year":"2016","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.ymthe.2024.07.011_bib23","doi-asserted-by":"crossref","first-page":"447","DOI":"10.3389\/fonc.2018.00447","article-title":"Cancer Site-Specific Multiple microRNA Quantification by Droplet Digital PCR","volume":"8","author":"Laprovitera","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ymthe.2024.07.011_bib24","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1158\/2159-8290.CD-21-1547","article-title":"AACR Project GENIE: 100,000 Cases and Beyond","volume":"12","author":"Pugh","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ymthe.2024.07.011_bib25","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1002\/jcp.24649","article-title":"Isoforms of receptors of fibroblast growth factors","volume":"229","author":"Gong","year":"2014","journal-title":"J.\u00a0Cel. Physiol."},{"key":"10.1016\/j.ymthe.2024.07.011_bib26","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1006\/dbio.1993.1205","article-title":"Developmental localization of the splicing alternatives of fibroblast growth factor receptor-2 (FGFR2)","volume":"158","author":"Orr-Urtreger","year":"1993","journal-title":"Dev. Biol."},{"key":"10.1016\/j.ymthe.2024.07.011_bib27","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1158\/1535-7163.MCT-19-0931","article-title":"FGFR Inhibition Enhances Sensitivity to Radiation in Non-Small Cell Lung Cancer","volume":"19","author":"SenthilKumar","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ymthe.2024.07.011_bib28","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.15252\/emmm.201404208","article-title":"Epithelial-mesenchymal transition spectrum quantification and its efficacy in deciphering survival and drug responses of cancer patients","volume":"6","author":"Tan","year":"2014","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ymthe.2024.07.011_bib29","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12964-015-0106-x","article-title":"Stimulus-dependent differences in signalling regulate epithelial-mesenchymal plasticity and change the effects of drugs in breast cancer cell lines","volume":"13","author":"Cursons","year":"2015","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.ymthe.2024.07.011_bib30","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1038\/s41467-021-22643-w","article-title":"Cancer of unknown primary stem-like cells model multi-organ metastasis and unveil liability to MEK inhibition","volume":"12","author":"Verginelli","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2024.07.011_bib31","first-page":"233","article-title":"Cancer genomics and genetics of FGFR2 (Review)","volume":"33","author":"Katoh","year":"2008","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ymthe.2024.07.011_bib32","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1158\/2159-8290.CD-17-0057","article-title":"Gatekeeper Mutations and Intratumoral Heterogeneity in FGFR2-Translocated Cholangiocarcinoma","volume":"7","author":"Smyth","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ymthe.2024.07.011_bib33","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/nrc.2017.8","article-title":"Advances and challenges in targeting FGFR signalling in cancer","volume":"17","author":"Babina","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ymthe.2024.07.011_bib34","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1158\/1535-7163.MCT-17-0464","article-title":"RAS-MAPK Reactivation Facilitates Acquired Resistance in FGFR1-Amplified Lung Cancer and Underlies a Rationale for Upfront FGFR-MEK Blockade","volume":"17","author":"Bockorny","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ymthe.2024.07.011_bib35","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10585-012-9474-4","article-title":"Profiling immunohistochemical expression of NOTCH1-3, JAGGED1, cMET, and phospho-MAPK in 100 carcinomas of unknown primary","volume":"29","author":"Krikelis","year":"2012","journal-title":"Clin. Exp. Metastasis"},{"key":"10.1016\/j.ymthe.2024.07.011_bib36","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3389\/fonc.2019.00179","article-title":"Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines","volume":"9","author":"Fumarola","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ymthe.2024.07.011_bib37","doi-asserted-by":"crossref","first-page":"5527","DOI":"10.1158\/1078-0432.CCR-17-0478","article-title":"Mechanisms of Primary Drug Resistance in FGFR1-Amplified Lung Cancer","volume":"23","author":"Malchers","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2024.07.011_bib38","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/S1470-2045(22)00603-9","article-title":"Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study","volume":"23","author":"Wainberg","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ymthe.2024.07.011_bib39","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1158\/1538-7445.AM2022-302","article-title":"Abstract 302: MEKi-FGFRi combination nanoparticles for use against KRASmt\/FGFR-compensatory lung tumors","volume":"82","author":"Izawa-Ishiguro","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2024.07.011_bib40","doi-asserted-by":"crossref","first-page":"3298","DOI":"10.1016\/j.celrep.2017.11.051","article-title":"Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient Care","volume":"21","author":"Kodack","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.ymthe.2024.07.011_bib41","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkq603","article-title":"ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data","volume":"38","author":"Wang","year":"2010","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2024.07.011_bib42","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/s41586-020-2308-7","article-title":"The mutational constraint spectrum quantified from variation in 141,456 humans","volume":"581","author":"Karczewski","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2024.07.011_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nprot.2015.123","article-title":"SIFT missense predictions for genomes","volume":"11","author":"Vaser","year":"2016","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.ymthe.2024.07.011_bib44","article-title":"Predicting functional effect\u00a0of\u00a0human missense mutations using PolyPhen-2. Curr Protoc Hum Genet Chapter","volume":"Chapter 7","author":"Adzhubei","year":"2013","journal-title":"Curr. Protoc. Hum. Genet."},{"key":"10.1016\/j.ymthe.2024.07.011_bib45","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1101\/gr.092619.109","article-title":"Identification of deleterious mutations within three human genomes","volume":"19","author":"Chun","year":"2009","journal-title":"Genome Res."},{"key":"10.1016\/j.ymthe.2024.07.011_bib46","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nmeth.2890","article-title":"MutationTaster2: mutation prediction for the deep-sequencing age","volume":"11","author":"Schwarz","year":"2014","journal-title":"Nat. Methods"},{"key":"10.1016\/j.ymthe.2024.07.011_bib47","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkr407","article-title":"Predicting the functional impact of protein mutations: application to cancer genomics","volume":"39","author":"Reva","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2024.07.011_bib48","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/humu.22225","article-title":"Predicting the functional, molecular, and phenotypic consequences of amino acid substitutions using hidden Markov models","volume":"34","author":"Shihab","year":"2013","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.ymthe.2024.07.011_bib49","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/ng.2892","article-title":"A general framework for estimating the relative pathogenicity of human genetic variants","volume":"46","author":"Kircher","year":"2014","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ymthe.2024.07.011_bib50","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/humu.22911","article-title":"Assessing the Pathogenicity of Insertion and Deletion Variants with the Variant Effect Scoring Tool (VEST-Indel)","volume":"37","author":"Douville","year":"2016","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.ymthe.2024.07.011_bib51","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/s41592-023-01943-7","article-title":"Unsupervised removal of systematic background noise from droplet-based single-cell experiments using CellBender","volume":"20","author":"Fleming","year":"2023","journal-title":"Nat. Methods"},{"key":"10.1016\/j.ymthe.2024.07.011_bib52","doi-asserted-by":"crossref","first-page":"979","DOI":"10.12688\/f1000research.73600.1","article-title":"Doublet identification in single-cell sequencing data using scDblFinder","volume":"10","author":"Germain","year":"2021","journal-title":"F1000Res."},{"key":"10.1016\/j.ymthe.2024.07.011_bib53","doi-asserted-by":"crossref","first-page":"4383","DOI":"10.1038\/s41467-018-06318-7","article-title":"Single cell RNA sequencing of human liver reveals distinct intrahepatic macrophage populations","volume":"9","author":"MacParland","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2024.07.011_bib54","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","article-title":"Integrated analysis of multimodal single-cell data","volume":"184","author":"Hao","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2024.07.011_bib55","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13059-021-02584-9","article-title":"Comparison and evaluation of statistical error models for scRNA-seq","volume":"23","author":"Choudhary","year":"2022","journal-title":"Genome Biol."},{"key":"10.1016\/j.ymthe.2024.07.011_bib56","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkz826","article-title":"Latent cellular analysis robustly reveals subtle diversity in large-scale single-cell RNA-seq data","volume":"47","author":"Cheng","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2024.07.011_bib57","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1038\/s41467-022-28803-w","article-title":"Fully-automated and ultra-fast cell-type identification using specific marker combinations from single-cell transcriptomic data","volume":"13","author":"Ianevski","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2024.07.011_bib58","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/s13059-015-0844-5","article-title":"MAST: a flexible statistical framework for assessing transcriptional changes and characterizing heterogeneity in single-cell RNA sequencing data","volume":"16","author":"Finak","year":"2015","journal-title":"Genome Biol."},{"key":"10.1016\/j.ymthe.2024.07.011_bib59","article-title":"Fast gene set enrichment analysis","author":"Gennady Korotkevich","year":"2021","journal-title":"bioRxiv"},{"key":"10.1016\/j.ymthe.2024.07.011_bib60","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/s41416-020-01178-9","article-title":"EMTome: a resource for pan-cancer analysis of epithelial-mesenchymal transition genes and signatures","volume":"124","author":"Vasaikar","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ymthe.2024.07.011_bib61","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/sj.cdd.4401660","article-title":"Cell size reduction induced by inhibition of the mTOR\/S6K-signaling pathway protects Jurkat cells from apoptosis","volume":"12","author":"Fumarola","year":"2005","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.ymthe.2024.07.011_bib62","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.bcp.2009.04.033","article-title":"Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines","volume":"78","author":"La Monica","year":"2009","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ymthe.2024.07.011_bib63","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1158\/1535-7163.MCT-07-0477","article-title":"Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines","volume":"7","author":"Cavazzoni","year":"2008","journal-title":"Mol. Cancer Ther."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001624004660?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001624004660?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T12:50:10Z","timestamp":1758199810000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001624004660"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":63,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S1525001624004660"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2024.07.011","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.03.12.23287041","asserted-by":"object"}]},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synergic activity of FGFR2 and MEK inhibitors in the treatment of FGFR2-amplified cancers of unknown primary","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2024.07.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}